Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

27.12 -0.79 (-2.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
51 Biggest Movers From Yesterday ↗
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are... 
Via Benzinga
News headline image
Castle Biosciences Adds Mental Health Testing Solutions Via AltheaDx Acquisition ↗
Castle Biosciences Inc (NASDAQ: CSTL) has agreed to acquire AltheaDx Inc, a commercial-stage molecular diagnostics company,  
Via Benzinga
News headline image
Castle Biosciences to Acquire AltheaDx
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences: Q4 Earnings Insights ↗
Castle Biosciences (NASDAQ:CSTL) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases
Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few... 
Via FinancialNewsMedia
Topics Intellectual Property
News headline image
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the 24th Annual Needham Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Completes Acquisition of Cernostics
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 ↗
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
News headline image
Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Named in Inc.’s First-Annual Best-Led Companies
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Named a 2021 Houston Chronicle Top Workplace
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Third Quarter 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm
From Castle Biosciences, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.